Elanco Animal Health Incorporated $ELAN Stock Holdings Lowered by Deutsche Bank AG

Deutsche Bank AG reduced its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 76.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 244,542 shares of the company’s stock after selling 792,535 shares during the quarter. Deutsche Bank AG’s holdings in Elanco Animal Health were worth $2,568,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ELAN. Allworth Financial LP raised its holdings in shares of Elanco Animal Health by 791.7% in the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after purchasing an additional 2,090 shares in the last quarter. CoreCap Advisors LLC bought a new stake in shares of Elanco Animal Health in the 4th quarter worth approximately $29,000. NBC Securities Inc. bought a new stake in shares of Elanco Animal Health in the 1st quarter worth approximately $40,000. Parallel Advisors LLC raised its holdings in shares of Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock worth $41,000 after purchasing an additional 1,852 shares in the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock worth $46,000 after purchasing an additional 1,740 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Stock Performance

ELAN stock opened at $17.5250 on Wednesday. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $8.71 billion, a price-to-earnings ratio of 20.38, a P/E/G ratio of 3.29 and a beta of 1.66. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.08. The firm has a 50 day moving average of $14.87 and a two-hundred day moving average of $12.35.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.20 by $0.06. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ELAN. William Blair raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research report on Thursday, June 26th. Wall Street Zen raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a research report on Saturday, July 5th. Stifel Nicolaus lifted their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Wednesday, July 2nd. Leerink Partnrs raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. Finally, UBS Group lifted their target price on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $17.33.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.